Clinical trial

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

NCT03786107

StatusTERMINATED

Study typeOBSERVATIONAL

Start date2019-03-14

PhaseN/A

Study timeline

Study start (actual)2019-03-14Date precision: day

Registry last updated2021-05-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancerunresolved

Metastatic Cervical Cancerunresolved

Interventions

Almac HER-Seq AssayDIAGNOSTIC_TEST

Sponsors & collaborators

Puma Biotechnology, Inc.lead sponsor

Mapped research locations

MadridSpain3 BarcelonaSpain3 ValenciaSpain2 DublinIreland2 PittsburghPennsylvania, United States1 NaplesItaly1 Tel AvivIsrael1 Ramat GanIsrael1 BelgradeSerbia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03786107 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.